A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment
Background. Recent clinical trials proven the clinically significant efficacy and tolerability of nivolumab, a programmed death 1 (PD-1) inhibitor, in previously treated patients with non-small cell lung cancer (NSCLC). Case Presentation. Here, we describe the case of a patient who experienced possi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2016/1075641 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546599995179008 |
|---|---|
| author | Shotaro Chubachi Hiroyuki Yasuda Hidehiro Irie Koichi Fukunaga Katsuhiko Naoki Kenzo Soejima Tomoko Betsuyaku |
| author_facet | Shotaro Chubachi Hiroyuki Yasuda Hidehiro Irie Koichi Fukunaga Katsuhiko Naoki Kenzo Soejima Tomoko Betsuyaku |
| author_sort | Shotaro Chubachi |
| collection | DOAJ |
| description | Background. Recent clinical trials proven the clinically significant efficacy and tolerability of nivolumab, a programmed death 1 (PD-1) inhibitor, in previously treated patients with non-small cell lung cancer (NSCLC). Case Presentation. Here, we describe the case of a patient who experienced possible “disease flare” immediately after initiation of nivolumab treatment. A 54-year-old man was diagnosed with Stage IIB (T2N1M0) lung adenocarcinoma. After 7 years from recurrence, 10th line chemotherapy, nivolumab, was initiated. Six weeks later, after 3 cycles of nivolumab treatment, rapid lung cancer progression was observed with an increase in the size of the primary lesion, multiple novel nodules on both lungs, and multiple novel brain metastases. Conclusion. We believe that physicians should be made aware that, in a subset of NSCLC patients, disease flare might occur on nivolumab treatment. |
| format | Article |
| id | doaj-art-5a0a0f638899439a92aad9afc03bb258 |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-5a0a0f638899439a92aad9afc03bb2582025-02-03T06:47:56ZengWileyCase Reports in Oncological Medicine2090-67062090-67142016-01-01201610.1155/2016/10756411075641A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab TreatmentShotaro Chubachi0Hiroyuki Yasuda1Hidehiro Irie2Koichi Fukunaga3Katsuhiko Naoki4Kenzo Soejima5Tomoko Betsuyaku6Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, JapanDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, JapanDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, JapanDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, JapanDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, JapanDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, JapanDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, JapanBackground. Recent clinical trials proven the clinically significant efficacy and tolerability of nivolumab, a programmed death 1 (PD-1) inhibitor, in previously treated patients with non-small cell lung cancer (NSCLC). Case Presentation. Here, we describe the case of a patient who experienced possible “disease flare” immediately after initiation of nivolumab treatment. A 54-year-old man was diagnosed with Stage IIB (T2N1M0) lung adenocarcinoma. After 7 years from recurrence, 10th line chemotherapy, nivolumab, was initiated. Six weeks later, after 3 cycles of nivolumab treatment, rapid lung cancer progression was observed with an increase in the size of the primary lesion, multiple novel nodules on both lungs, and multiple novel brain metastases. Conclusion. We believe that physicians should be made aware that, in a subset of NSCLC patients, disease flare might occur on nivolumab treatment.http://dx.doi.org/10.1155/2016/1075641 |
| spellingShingle | Shotaro Chubachi Hiroyuki Yasuda Hidehiro Irie Koichi Fukunaga Katsuhiko Naoki Kenzo Soejima Tomoko Betsuyaku A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment Case Reports in Oncological Medicine |
| title | A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment |
| title_full | A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment |
| title_fullStr | A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment |
| title_full_unstemmed | A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment |
| title_short | A Case of Non-Small Cell Lung Cancer with Possible “Disease Flare” on Nivolumab Treatment |
| title_sort | case of non small cell lung cancer with possible disease flare on nivolumab treatment |
| url | http://dx.doi.org/10.1155/2016/1075641 |
| work_keys_str_mv | AT shotarochubachi acaseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment AT hiroyukiyasuda acaseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment AT hidehiroirie acaseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment AT koichifukunaga acaseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment AT katsuhikonaoki acaseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment AT kenzosoejima acaseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment AT tomokobetsuyaku acaseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment AT shotarochubachi caseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment AT hiroyukiyasuda caseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment AT hidehiroirie caseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment AT koichifukunaga caseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment AT katsuhikonaoki caseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment AT kenzosoejima caseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment AT tomokobetsuyaku caseofnonsmallcelllungcancerwithpossiblediseaseflareonnivolumabtreatment |